An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DSM-IV confirmed ADHD. Three week washout between each treatment period. CYP2D6 genotyping will be completed at screening and slow metabolisers will be excluded from participation in this study. Cognitive, ADHD symptom, safety and pharmacokinetic (PK) assessments will be made during each treatment period. Safety and tolerability assessments will be a major component of the trial and all serious adverse events (SAE) will be immediately (within 24 hours) reported to both Targacept and to AstraZenca.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Confirmed diagnosis of DSM-IV ADHD
- Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the Connor´s Adult ADHD Rating Scale (CAARS-INV)
- Score of equal or more than 4 (at least moderate severity) on the Clinical Global Impressions-Severity (CGI-S) test
Exclusion criteria
- Current DSM-IV Axis I psychiatric disorder (other than ADHD)
- Current user of cigarettes or other nicotine-containing product.
- Slow metabolizers as indicated by CYP2D6 genotyping.
- Use of drugs affecting cognitive function within 8 weeks prior to enrollment visit or intended use during the study.
Trial design
Primary purpose
Allocation
Interventional model
Masking
24 participants in 3 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal